Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Liabilities and Shareholders Equity: 2024-2025

Historic Liabilities and Shareholders Equity for Pyxis Oncology (PYXS) over the last 2 years, with Sep 2025 value amounting to $105.6 million.

  • Pyxis Oncology's Liabilities and Shareholders Equity fell 45.93% to $105.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $521.9 million, marking a year-over-year change of. This contributed to the annual value of $157.2 million for FY2024, which is N/A change from last year.
  • Pyxis Oncology's Liabilities and Shareholders Equity amounted to $105.6 million in Q3 2025, which was down 14.29% from $123.2 million recorded in Q2 2025.
  • In the past 5 years, Pyxis Oncology's Liabilities and Shareholders Equity ranged from a high of $220.2 million in Q1 2024 and a low of $105.6 million during Q3 2025.
  • For the 2-year period, Pyxis Oncology's Liabilities and Shareholders Equity averaged around $163.7 million, with its median value being $157.2 million (2024).
  • Data for Pyxis Oncology's Liabilities and Shareholders Equity shows a maximum YoY tumbled of 45.93% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Pyxis Oncology's Liabilities and Shareholders Equity stood at $157.2 million in 2024, then plummeted by 45.93% to $105.6 million in 2025.
  • Its last three reported values are $105.6 million in Q3 2025, $123.2 million for Q2 2025, and $135.9 million during Q1 2025.